Pharmacy Lien Agreements in Discovery: What Attorneys Must (and Don't Have to) Produce

James Wong — Founder & Pharmacist, LienScripts | June 10, 2025 | 8 min read

Defense counsel increasingly requests pharmacy lien agreements and billing records as part of PI discovery. Here is what is generally discoverable, what is not, and how to respond to overbroad requests without creating unnecessary conflict.

[!KEY] Defense discovery requests targeting pharmacy lien documents serve three strategic goals: challenging pricing reasonableness, attacking clinical documentation bias, and finding procedural lien defects — knowing this shapes how you respond.

Defense Is Asking for These Documents More Often

Pharmacy lien discovery requests have become a predictable part of PI litigation in California. Defense counsel knows that a pharmacy lien is in place — often because the MERIT report references it, or because billing records include lien-based charges — and they have developed a standard discovery playbook to challenge those charges and attack the credibility of the clinical documentation.

Understanding what you are required to produce, what you can legitimately object to, and how to frame your responses gives you a significant advantage in managing this discovery category.

What Defense Is Actually After

Defense requests for pharmacy lien documents typically serve one or more of three strategic goals:

Challenge the reasonableness of medical specials. Defense will argue that lien-based billing is not reflective of the "reasonable value" of the medications — that lien pricing is artificially elevated compared to what the medications would cost through insurance or at a retail pharmacy. This is a substantive damages argument, and it requires them to understand the structure of the lien.

Create a bias narrative around clinical documentation. When the MERIT report or pharmacy narrative is submitted as evidence of medical necessity, defense will argue that the pharmacist who prepared it has a financial interest in the outcome of the case — that the clinical conclusions are corrupted by the financial relationship. The documents they request are meant to support this narrative.

Identify procedural vulnerabilities in the lien itself. A lien that was improperly executed, signed after medications were already dispensed, or that contains unusual terms may have enforceability issues that could affect damages. Defense counsel is looking for technical defects.

Knowing these goals helps you respond strategically — produce what is required, object to what is not, and prepare your experts to address the bias argument directly.

What Is Generally Discoverable

The existence of the pharmacy lien is almost certainly discoverable. It is a financial arrangement that directly bears on the nature and amount of the claimed medical specials. If defense requests confirmation that a pharmacy lien exists, provide it.

The pharmacy lien agreement itself is generally discoverable when it relates to the services provided and the basis for the claimed damages. The lien agreement establishes the terms under which medications were provided and repayment is to occur — information that is directly relevant to the medical specials claim.

Pharmacy billing records and dispensing records are discoverable. They are the underlying documentation for the medical special damages claimed. A lien-based billing model does not insulate the records from discovery — the records describe what medications were dispensed, on what dates, and at what charges. This is standard medical record discovery.

The MERIT report (the pharmacist's clinical narrative) is discoverable if it is being offered as evidence. The MERIT report is a clinical opinion document that defense is entitled to examine and challenge.

[!KEY] When the MERIT report is produced in discovery, prepare a brief declaration addressing the bias argument before defense can file a motion to exclude — the pharmacist's regulatory accountability and the non-recourse lien structure are your strongest responses.

What Is Generally Not Discoverable

The pharmacy lien provider's internal cost structure — the relationship between the lien provider's acquisition costs and the lien charges — is not relevant to the reasonable value of medical services and is not discoverable. California courts applying the Howell v. Hamilton framework focus on the reasonable value of services, not on the provider's internal economics. A request for the lien provider's internal pricing data, cost sheets, or business records goes well beyond what is necessary to evaluate damages.

Internal communications about case strategy between the attorney and the pharmacy lien provider may be protected, depending on the nature of those communications. Communications that are purely operational (enrollment, prescription processing) are not privileged. Communications that involve legal strategy or that were made in anticipation of litigation may warrant privilege protection. Evaluate these case by case.

Rate negotiations between the lien provider and third parties — for example, any arrangements the lien provider has with other attorneys or other institutional parties — are not relevant to the specific case and are not discoverable.

The Bias Argument Against Clinical Documentation

Defense will argue that the pharmacist who prepared the MERIT report has a financial interest in the outcome of the case — because the lien provider is repaid only if there is a recovery. This argument sounds damaging, but it has significant weaknesses that you should be prepared to address:

The non-recourse structure cuts both ways. The lien provider is repaid from settlement proceeds only if there is a recovery. But if the case produces no recovery, the lien is waived. This means the lien provider does not benefit from a bad outcome for the client — they benefit from an accurate clinical record that supports a strong recovery. Defense's attempt to characterize the lien provider as biased toward inflating damages ignores the fact that an inflated clinical narrative that fails at trial benefits no one.

The dispensing records are objective transaction records. The pharmacy did or did not fill a specific prescription on a specific date. These are factual records, not opinions. Defense bias arguments apply to the clinical narrative components of the MERIT — not to the underlying dispensing records, which are inherently objective.

The pharmacist is a licensed professional subject to regulatory oversight. A MERIT report is signed by a licensed pharmacist who is subject to California State Board of Pharmacy oversight and faces professional consequences for making material misrepresentations in clinical documents. This is meaningfully different from a retained expert with no regulatory accountability.

Motion Practice: Protective Orders and Limitations

If defense serves a request for production that is overbroad — for example, seeking the lien provider's internal financials, proprietary pricing data, or attorney-client communications — a motion for protective order is appropriate.

[!KEY] A motion for protective order under CCP § 2025.420 is the correct response to requests for the lien provider's internal pricing data — the relevant question under Howell is the reasonable market value of the medications, not the provider's internal economics.

California CCP section 2025.420 allows the court to issue a protective order limiting the scope of discovery when a request seeks information that is irrelevant, privileged, or would result in undue burden or invasion of a third party's proprietary information. The lien provider's internal business records are a strong candidate for protective order treatment.

When opposing a protective order, defense will likely argue that the pricing information is relevant to the reasonableness of the medical specials under Howell. Your response: Howell requires evidence of what the plaintiff actually received and what the defendant owes — not the lien provider's internal economics. The relevant question is the reasonable market value of the medications provided, which can be established through other means.

The Practical Approach

[!TIP] Produce the lien agreement and billing records promptly — delay only creates conflict and suggests you have something to conceal, while producing them quickly signals confidence in the documentation's strength.

Be prepared for pharmacy lien discovery in every case where a lien is in place. Develop a standard response protocol:

1. Produce the lien agreement and billing records promptly — this is required, and delay only creates conflict and suggests you have something to hide.
2. Object specifically and in writing to any request for the lien provider's internal financials or pricing structure.
3. Prepare a standard declaration or brief addressing the bias argument for use when the MERIT is submitted as evidence.
4. Work with the pharmacy lien provider to ensure that billing documentation is complete, accurate, and consistently formatted before litigation — sloppy records invite more aggressive discovery.

This post is for informational purposes and does not constitute legal advice. Consult your own ethics counsel for guidance on your specific situation.

Related Resources

• California RPC and Pharmacy Liens: Your Complete Fiduciary Obligations
• Expert Witness Pharmacy Testimony in PI Cases
• Pharmacy Records and Causation Expert Testimony
• Trial Preparation: Using Pharmacy Evidence
• Pharmacy Services for Personal Injury Clients: How It Works
• What Are Medication Liens?